Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada

BACKGROUND: To address a high incidence of serogroup B invasive meningococcal disease (IMD-B) in the Saguenay-Lac-Saint-Jean region, Quebec, Canada, a mass vaccination campaign targeting nearly 60,000 individuals ≤20 years old was launched in May 2014. Because of the limited clinical experience with the four-component meningococcal B vaccine (4CMenB), active surveillance for adverse events following immunization (AEFI) was conducted. This paper reports 4CMenB AEFI surveillance findings. METHODS: Active surveillance assessed AEFIs with acute onset within 7-days post-immunization, AEFI-associated absenteeism and medical consultations, impact of antipyretic prophylaxis and coadministration of other vaccines. RESULTS: By July 17, 2015, 83% and 77% of the 59,098 individuals targeted by the campaign had received a first and a second dose of 4CMenB. The incidence of fever on days1-2 was highest in children
Auteurs (Zotero)
De Serres, Gaston; Billard, Marie-Noëlle; Gariépy, Marie-Claude; Rouleau, Isabelle; Toth, Eveline; Landry, Monique; Boulianne, Nicole; Gagné, Hélène; Gilca, Vladimir; Deceuninck, Geneviève; Ouakki, Manale; Skowronski, Danuta M.
Date de publication (Zotero)
janvier, 2018